期刊
JOURNAL OF IMMUNOTHERAPY
卷 33, 期 6, 页码 591-598出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CJI.0b013e3181dda207
关键词
neuroblastoma; gamma delta T cells; BrHPP; amplification; autologous lysis
资金
- Comite Departemental de l'Ain
- Comite Departemental de la Savoie
- Comite Departemental de Saone et Loire de la Ligue de Lutte Contre le Cancer
Gamma/delta T cells (V gamma 9 delta 2) contribute to innate immunity and exert natural cytotoxicity against a variety of tumors. Using a synthetic phosphoantigen (Bromohydrin Pyrophosphate, BrHPP), we amplified V gamma 9 delta 2 T cells in vitro from neuroblastoma patients. In the presence of BrHPP and low doses of IL-2, robust proliferation of V gamma 9 delta 2 T cells was obtained from peripheral blood mononuclear cells (PBMC) harvested at diagnosis. Moderate proliferation was observed from PBMC harvested after stem cell transplantation, whereas modest levels of V gamma 9 delta 2 T cells were obtained from PBMC harvested after induction therapy. Proliferation was observed after a single in vitro stimulation with BrHPP. After 21 days in culture, V gamma 9 delta 2 T cells represented more than 80% of cultured cells (a 50-fold expansion from baseline). Moreover, BrHPP-amplified V gamma 9 delta 2 T cells from patients-expressed activation markers and were able to lyse allogeneic and autologous neuroblasts. This cytotoxic activity was gamma delta T-cell receptor-dependent. Clinical trials using BrHPP are warranted in patients with poor-prognosis neuroblastoma, either to expand patient-derived V gamma 9 delta 2 T cells ex vivo or by direct administration to in vivo to boost the pool of resident V gamma 9 delta 2 T cells in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据